A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo.

@article{Chen2015ANT,
  title={A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo.},
  author={Thomas C Chen and Hee-yeon Cho and Weijun Wang and Jenny Nguyen and Niyati Jhaveri and Rachel Rosenstein-Sisson and Florence M. Hofman and Axel H Sch{\"o}nthal},
  journal={Cancer letters},
  year={2015},
  volume={358 2},
  pages={
          144-151
        }
}
The alkylating agent temozolomide (TMZ) represents an important component of current melanoma therapy, but overexpression of O6-methyl-guanine DNA methyltransferase (MGMT) in tumor cells confers resistance to TMZ and impairs therapeutic outcome. We investigated a novel perillyl alcohol (POH)-conjugated analog of TMZ, NEO212, for its ability to exert anticancer activity against MGMT-positive melanoma cells. Human melanoma cells with variable MGMT expression levels were treated with NEO212, TMZ… Expand
C8-Substituted Imidazotetrazine Analogs Overcome Temozolomide Resistance by Inducing DNA Adducts and DNA Damage
TLDR
C8 analogs of TMZ share a mechanism of action similar to TMZ and are able to methylate DNA generating O6-methylguanine adducts, but unlike TMZ are able at least in part to thwart MGMT- and MMR-mediated resistance. Expand
Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia
TLDR
In vivo and in vitro experiments show that treatment of cells with NEO212 results in growth inhibition via potent G2 arrest, which is followed by apoptotic cell death, and suggests that NEO212 should be developed further toward clinical testing. Expand
Cytotoxic impact of a perillyl alcohol–temozolomide conjugate, NEO212, on cutaneous T-cell lymphoma in vitro
TLDR
The generation of reactive oxygen species (ROS) appears to play a key role in the NEO212-induced cell death process, because the blockage of ROS with antioxidants prevented caspase activation. Expand
A novel series of phenolic temozolomide (TMZ) esters with 4 to 5-fold increased potency, compared to TMZ, against glioma cells irrespective of MGMT expression
The standard of care treatment for patients diagnosed with glioblastoma multiforme (GBM) is temozolomide (TMZ). Tumour resistance to TMZ results in significantly limited clinical effectiveness. ThereExpand
Cinnamaldehyde Enhances Antimelanoma Activity through Covalently Binding ENO1 and Exhibits a Promoting Effect with Dacarbazine
TLDR
Cinnamaldehyde (CA) is presented as a potential candidate, which exerted an antitumor effect in melanoma cell lines and dacarbazine (DTIC) showed a high promoting effect with CA for antimelanoma both in vivo and in vitro. Expand
A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
TLDR
In vivo studies show that NEO212 significantly delays tumor growth of both proneural and mesenchymal tumor stem cell populations, indicating that NEO 212 has great clinical potential to effectively target GBM. Expand
Pharmacokinetic properties of the temozolomide perillyl alcohol conjugate (NEO212) in mice
TLDR
NEO212 preferentially concentrates in brain tumor tissue over normal brain tissue, and compared to TMZ has a higher brain:plasma ratio, altogether revealing favorable features to encourage its further development as a brain-targeted therapeutic. Expand
NEO412: A temozolomide analog with transdermal activity in melanoma in vitro and in vivo
TLDR
In vivo and in vitro results showed that NEO412 effectively killed melanoma cells, including TMZ-resistant and BRAF mutant ones, through DNA alkylation and subsequent apoptosis, and presented NEO412 as a potentially promising new treatment for cutaneous melanoma, in particular MIS, deserving of further study. Expand
Therapeutic effect of TMZ-POH on human nasopharyngeal carcinoma depends on reactive oxygen species accumulation
TLDR
The cytotoxicity effects of a newly patented compound temozolomide–perillyl alcohol (TMZ-POH) on NPC in vitro and in vivo, and the possible mechanisms involved are demonstrated, indicated that TMZ-P OH could inhibit NPC cell proliferation, cause G2/M arrest and DNA damage. Expand
NEO212 Inhibits Migration and Invasion of Glioma Stem Cells
TLDR
In an in vivo orthotopic glioma model, NEO212 decreases tumor progression by reducing invasion of GSCs, thereby increasing survival time of mice, and indicates that NEO212, in addition to cytotoxicity, can effectively reduce migration and invasion in G SCs, thus exhibiting significant clinical value in the reduction of invasion and malignant gliomas progression. Expand
...
1
2
...

References

SHOWING 1-10 OF 67 REFERENCES
NEO212, Temozolomide Conjugated to Perillyl Alcohol, Is a Novel Drug for Effective Treatment of a Broad Range of Temozolomide-Resistant Gliomas
TLDR
NEO212 functions as a DNA alkylating agent, similar to temozolomide; however, this novel conjugate is unique for it may induce endoplasmic reticulum (ER) stress and inhibits autophagy. Expand
A Novel Temozolomide–Perillyl Alcohol Conjugate Exhibits Superior Activity against Breast Cancer Cells In Vitro and Intracranial Triple-Negative Tumor Growth In Vivo
TLDR
In an intracranial mouse tumor model with triple-negative breast cancer, T-P revealed considerably greater therapeutic efficacy than TMZ, where a single cycle of treatment extended median survival benefit from 6 days to 28 days, and seemed to be well tolerated by the animals. Expand
Temozolomide: mechanisms of action, repair and resistance.
TLDR
Several small molecule inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1), a critical BER protein are yielding promising results clinically, both in combination with TMZ and as single agent chemotherapy in patients whose tumours possess homologous recombination DNA repair defects. Expand
Temozolomide: mechanisms of action, repair and resistance.
TLDR
Several small molecule inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1), a critical BER protein are yielding promising results clinically, both in combination with TMZ and as single agent chemotherapy in patients whose tumours possess homologous recombination DNA repair defects. Expand
Perillyl Alcohol for the Treatment of Temozolomide-Resistant Gliomas
TLDR
The data show that POH is an effective anti-glioma cytotoxic agent for TMZ-resistant gliomas when administered intranasally and impeded survival pathways, such as mTOR and Ras. Expand
p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells.
TLDR
The results suggest that glioma cells respond to TMZ by undergoing G2-M arrest, and the integrity of the G1-M cell cycle checkpoint may be important in the cytotoxicity of TMZ in gliomas. Expand
O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems.
TLDR
Observations suggest a role for MGMT in directing adjuvant therapy of GBM and other gliomas, and approaches that may improve the utility of MGMT methylation status in planning optimal therapies tailored to individual patients are considered. Expand
Targeting O6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy
TLDR
It is anticipated that, with the availability of tumour targeting strategies and hematopoetic stem cell protection, MGMT inactivators hold promise for enhancing the effectiveness of alkylating agent chemotherapy. Expand
Challenging resistance mechanisms to therapies for metastatic melanoma.
TLDR
The implications of simultaneously targeting key regulators of melanoma cell proliferation/survival and immune responses to counteract resistance are discussed. Expand
Inhibition of tumor cell growth by monoterpenes in vitro: evidence of a Ras-independent mechanism of action
TLDR
Although effective in inhibiting the growth of tumor cells harboring activated ras oncogenes, limonene and (+)-perillyl alcohol are unlikely to act by inhibiting Ras function. Expand
...
1
2
3
4
5
...